Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

被引：0
|
作者：
Jun Guo
Yiran Huang
Xu Zhang
Fangjian Zhou
Yinghao Sun
Shukui Qin
Zhangqun Ye
Hui Wang
Annette Jappe
Patrick Straub
Nicoletta Pirotta
Sven Gogov
机构：
[1] Peking University Cancer Hospital and Institute,
[2] Shanghai Renji Hospital,undefined
[3] The General Hospital of PLA,undefined
[4] Sun Yat-sen University Cancer Center,undefined
[5] Shanghai Changhai Hospital,undefined
[6] Nanjing Bayi Hospital,undefined
[7] Wuhan Tongji Hospital,undefined
[8] Beijing Novartis Pharma Company,undefined
[9] Ltd.,undefined
[10] Novartis Pharma AG,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharma AG,undefined
[13] Novartis Pharma AG,undefined
来源：
BMC Cancer | / 13卷
关键词：
Asian; Everolimus; mTOR inhibitor; Renal cell cancer; Sunitinib; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma
    Nuri Lee
    Jae Lyun Lee
    Ju-Yeun Lee
    Targeted Oncology, 2023, 18 : 247 - 255
  • [42] A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the safety and efficacy of RX-0201 in combination with everolimus to treat subjects with advanced renal cell carcinoma.
    Peterson, Christine
    Benaim, Ely
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the phase III RECORD-1 study
    Figlin, R. A.
    Calvo, E.
    Motzer, R. J.
    Hutson, T. E.
    Oudard, S.
    Porta, C.
    Grunwald, V.
    Ravaud, A.
    Kpamegan, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [44] Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
    Johnston, Hartlee
    Deal, Allison M.
    Morgan, Katherine P.
    Patel, Bianka
    Milowsky, Matthew I.
    Rose, Tracy L.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 357 - 365
  • [45] Correlation of Degree of Hypothyroidism With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
    Bailey, Erin B.
    Tantravahi, Srinivas K.
    Poole, Austin
    Agarwal, Archana M.
    Straubhar, Alli M.
    Batten, Julia A.
    Patel, Shiven B.
    Wells, Chesley E.
    Stenehjem, David D.
    Agarwal, Neeraj
    CLINICAL GENITOURINARY CANCER, 2015, 13 (03) : E131 - E137
  • [46] Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study
    Atkins, Michael B.
    Ravaud, Alain
    Gravis, Gwenaelle
    Drosik, Kazimierz
    Demkow, Tomasz
    Tomczak, Piotr
    Kracht, Karolyn
    Puhlmann, Markus
    Weinreich, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
    Korkmaz, Mustafa
    Eryilmaz, Melek K.
    Kocak, Mehmet Z.
    Er, Muhammed M.
    Hendem, Engin
    Demirkiran, Aykut
    Araz, Murat
    Karaagac, Mustafa
    Artac, Mehmet
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S160 - S165
  • [48] Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
    Liu, Rongrui
    Liu, Lianke
    Zhao, Chuanhua
    Bai, Yuxian
    Zheng, Yulong
    Zhang, Shu
    Li, Ning
    Yang, Jianwei
    Fan, Qingxia
    Wang, Xiuwen
    Zeng, Shan
    Zhang, Yingjun
    Zhang, Weihong
    Zhuang, Yulei
    Kang, Ning
    Jiang, Yingzhi
    Sun, Hongmei
    Xu, Jianming
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [49] Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
    Rongrui Liu
    Lianke Liu
    Chuanhua Zhao
    Yuxian Bai
    Yulong Zheng
    Shu Zhang
    Ning Li
    Jianwei Yang
    Qingxia Fan
    Xiuwen Wang
    Shan Zeng
    Yingjun Zhang
    Weihong Zhang
    Yulei Zhuang
    Ning Kang
    Yingzhi Jiang
    Hongmei Sun
    Jianming Xu
    BMC Gastroenterology, 21
  • [50] Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors
    Pal, Sumanta K.
    Li, Sierra M.
    Wu, Xiwei
    Qin, Hanjun
    Kortylewski, Marcin
    Hsu, Joann
    Carmichael, Courtney
    Frankel, Paul
    CLINICAL CANCER RESEARCH, 2015, 21 (23) : 5286 - 5293
12345